Vadadustat for COVID-19: real-time analysis

Download Image

Post

c19early.org

Vadadustat for COVID-19

1 study with 448 patients

Serious outcome risk

Vadadustat

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Vadadustat studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−3%

Mortality (1)−3%

RCTs (1)−3%

Late (1)−3%

00.511.5+

← Vadadustat
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Mar 25 2025	Bobrow et al., NCT04478071	Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Mar 25 2025	3% higher mortality (p=1), 16% lower progression (p=0.36), and 8% improved recovery (p=0.6). RCT 448 hospitalized COVID-19 patients in the USA showing no significant differences with vadadustat.